As governments rise to the challenge of managing the interlinked dynamics of population health and economic uncertainty, At a turning point: Healthcare systems in Central and Eastern Europe highlights the key differences and commonalities in healthcare financing and policy approaches across 13 European countries. The report, written by the Economist Impact, identifies major trends and aims to benchmark access and provision of healthcare services, medicines, healthcare outcomes as well as quality of care. It also puts forward a number of recommendations for action, in areas such as financing models, delivery of care, access to innovative treatments, diagnostics and digital infrastructure.
At a turning point: Healthcare systems in Central and Eastern Europe
As governments rise to the challenge of managing the interlinked dynamics of population health and economic uncertainty, At a turning point: Healthcare systems in Central and Eastern Europe highlights the key differences and commonalities in healthcare financing and policy approaches across 13 European countries. The report, written by the Economist Impact, identifies major trends and aims to benchmark access and provision of healthcare services, medicines, healthcare outcomes as well as quality of care. It also puts forward a number of recommendations for action, in areas such as financing models, delivery of care, access to innovative treatments, diagnostics and digital infrastructure.
A series of country profiles complement the study, featuring detailed data and additional analysis on the national dynamics. Country profiles are available for seven of the CEE countries: Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovakia and Slovenia. Romania has been included in this study as a comparator country. Additionally, you can find here a presentation outlining the background and objectives of the main study, as well as the key findings and recommendations for action.
Related items
Position Paper
11 Nov 2025
Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.
:focal())
News
27 Oct 2025
Advancing EU health policy through competitiveness and innovation
On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.
:focal())
News
9 Oct 2025
Advancing European healthcare in Strasbourg
From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.